

27 **Disclosure**

28 Conflicts of interests have been declared by the following authors: CL, LT, VO, are employees
29 of PhagoMed Biopharma GmbH at the time of the study and LC holds shares in PhagoMed
30 Biopharma GmbH and is the inventor on a patent application related to the work described here.
31 The research of AS, AL, LVS and MV has been supported financially by PhagoMed Biopharma
32 GmbH.

33 **Funding**

34 This study was supported by the Austrian Research Promotion Agency (FFG).

35 **Ethics approval**

36 The study was approved by the Charité ethical committee EA1 /088110.

37 **Word count of the abstract**

38 343 words

39 **Word count of the main text**

40 5434 words

- 41 **Keywords:** *Gardnerella*, prophage, endolysin, bacterial vaginosis, polymicrobial biofilm,
42 genus-specificity, antimicrobial resistance, alternative to antibiotic treatment

43 **Background** - Bacterial vaginosis is characterized by an imbalance of the vaginal microbiome
44 in which the normally predominant lactobacilli are replaced by other bacterial species. Initiated
45 by strains of the bacterium *Gardnerella*, a characteristic biofilm forms on the vaginal
46 epithelium, explaining the typical presence of clue cells. This biofilm contributes to the
47 resilience of the bacteria to antibiotic treatment, which may explain the frequent recurrence of
48 BV.

49 **Objective** - In this study, we investigate whether a therapy based on bacteriophage endolysins
50 which specifically lyse *Gardnerella*, in particular the drug candidate PM-477, might be a
51 promising alternative to broad-spectrum antibiotics and antiseptics.

52 **Study design** - To identify *Gardnerella* specific endolysins, we searched for endolysin-
53 encoding sequences in regions of *Gardnerella* genomes that are of prophage origin. This search
54 identified fourteen homologous genes predicted to encode 1,4-beta-N-acetylmuramidase-type
55 endolysins. When expressed in *Escherichia coli* and purified, the recombinant proteins
56 demonstrated strong bactericidal activity against four different *Gardnerella* species. By
57 shuffling the N-terminal catalytic domains and C-terminal cell wall-binding domains between
58 the homologues, we produced 81 chimeric endolysins. These endolysins were tested for their
59 activity and specificity *in vitro* and *ex-vivo* on vaginal samples from fifteen BV positive
60 patients. Fluorescence in situ hybridization was used for visualization.

61 **Results** - Several engineered endolysins were 10-fold more active than the most active wild-
62 type enzymes. When tested against a panel of 20 *Gardnerella* strains, the most active endolysin,
63 called PM-477, showed minimum inhibitory concentrations of 0.13–8 µg/ml. PM-477 had no
64 effect on *Lactobacillus* strains or other species of vaginal bacteria. Furthermore, the efficacy of
65 PM-477 was tested on vaginal samples from fifteen patients with either first time or recurring
66 bacterial vaginosis. In fourteen cases, PM-477 killed the *Gardnerella* bacteria and physically
67 dissolved the biofilms without affecting the remaining vaginal microbiome.

68 **Conclusion** - The high selectivity and effectiveness in eliminating *Gardnerella*, both in cultures
69 of isolated strains as well as in clinically derived samples of natural polymicrobial biofilms,
70 makes PM-477 a promising drug candidate and an alternative to antibiotics for the treatment of
71 bacterial vaginosis, especially in patients with frequent recurrence.

72 **Background**

73 Bacterial vaginosis (BV) is a very common disorder in women of reproductive age, with a
74 prevalence estimated at 10–30 % worldwide ^{1,2}. It is caused by an imbalance in the normal,
75 healthy microbiome of the vagina that results mostly in discharge, odor and irritation. BV is
76 associated with an increased risk of preterm delivery and low birthweight ^{3,4}, infertility and
77 early spontaneous abortion ^{5–7}, and it is also a high risk factor for contracting sexually
78 transmitted diseases, including HIV ^{8,9}. Besides these potentially severe physiological
79 consequences, frequently recurring and strongly symptomatic BV can have a huge negative
80 impact on some women's quality of life and psychological wellbeing.

81 The healthy vaginal microbiome is characterized by a low diversity and uniform colonization
82 by a few species of *Lactobacillus* ¹⁰. In BV, the imbalance in the vaginal microbiome is
83 represented predominantly by the loss of beneficial lactobacilli and overgrowth of bacteria such
84 as *Gardnerella*, *Prevotella*, *Atopobium*, and *Sneathia* ¹¹ and *Lactobacillus iners* ¹². The current
85 model of the etiology of BV focuses on the importance of *Gardnerella* species. It postulates
86 that virulent strains of *Gardnerella* form an adherent biofilm on the vaginal epithelium in which
87 other species can proliferate, resulting in a polymicrobial biofilm ^{13–17}. This adherent biofilm is
88 only weakly affected by the innate immune response ¹⁸, and the interplay with the host immune
89 system is only partially understood ¹⁹. BV development may be triggered by sexual transmission
90 of a mix of bacteria including *Gardnerella*, which can adhere to epithelial cells in the presence
91 of lactobacilli. It has been suggested that, unlike strictly anaerobic bacteria associated with BV,
92 *Gardnerella*, a facultative anaerobe, can tolerate the high redox potential created by the
93 *Lactobacillus*-dominated healthy vaginal microbiome ^{15,20,21}. The metabolism of *Gardnerella*
94 *spp.*, in turn, results in a local increase in pH and decrease of the redox potential, favoring
95 growth of iron-dependent anaerobes ¹⁰ and suppression of lactobacilli ²². Recently, the species
96 previously known as *Gardnerella vaginalis* was shown to comprise at least 13 different species
97 of which four were named ²³. Clinical studies indicated that various *Gardnerella* species may

98 contribute differently to the pathogenesis of BV. A higher abundance of *G. vaginalis* and *G.*
99 *swidsinskii* was found to be related with vaginal symptoms of abnormal odor and discharge and
100 the relative abundances of *G. vaginalis*, *G. swidsinskii*, and *G. piotii* but not *G. leopoldii* were
101 strongly associated with BV microbiome^{24,25}.

102 The therapies used currently to treat BV are broad-spectrum antibiotics, mainly metronidazole
103 (MDZ), tinidazole (TDZ), or clindamycin (CLI), antiseptics (such as Octenisept®, based on the
104 detergent-like octenidin), probiotics (preparations of lactobacilli), and prebiotics (lactate gels).
105 Although all of these treatments may have some beneficial effects, none has proven to have
106 satisfactory efficacy in preventing recurrence. Antibiotics are the most effective in quickly
107 reducing the symptoms, but they are associated with a recurrence rate of up to 60 % within six
108 months of treatment²⁶. One reason may be the presence of an antibiotic-tolerant biofilm in BV
109 that shelters a reservoir of persister cells^{26,27}. Antibiotic treatment not only often fails to
110 eradicate the biofilm, but can also lead to further dysbiosis of the vaginal microbiome and can
111 promote candidiasis²⁸. Moreover, CLI can trigger pseudomembranous colitis, cause antibiotics
112 associated diarrhea and other gastro-intestinal side effects^{29,30}. Also, *Gardnerella* strains
113 frequently develop resistance to MDZ and TDZ³¹. Antiseptic treatments for BV have been less
114 well studied than antibiotics but they are similar with regard to their effectiveness and are also
115 associated with high recurrence rates and deterioration of the healthy vaginal microbiome^{16,32}.
116 Studies of probiotics, and prebiotics are generally inconclusive: they appear not to result in
117 lasting benefits²⁶. Vaginal microbiome transplantation after a course of antibiotic treatment
118 had a promising effect in one study of five patients, but the approach is very resource-intense
119 and hardly scalable³³. In conclusion, novel treatments that offer an alternative to antibiotics or
120 that can be used in combination with antibiotics, are urgently needed.

121 Bacteriophage-encoded peptidoglycan hydrolases – also called endolysins or ‘enzybiotics’ –
122 are a promising alternative to antibiotics^{34,35}. Produced towards the end of the lytic cycle in
123 phage-infected bacteria, these enzymes cleave peptidoglycan in the bacterial cell wall, thus

124 lysing the cells and releasing the progeny phages. They have been shown to be particularly
125 effective against Gram-positive bacteria, which lack the Gram-negative outer membrane that
126 might limit accessibility to the cell wall peptidoglycan. Endolysins have several advantages
127 over antibiotics; not least, their very narrow host spectrum, which is usually limited to a single
128 genus or even a single species³⁶, and their low propensity to generate resistance in their hosts
129³⁷. Bacteriophages that invade Gram-positive bacteria encode a variety of highly diverse
130 endolysins. In general, they have a modular structure consisting of one or more enzymatically
131 active domain (EAD)s connected by a flexible interdomain linker to at least one cell wall-
132 binding domain (CBD), typically located at the C-terminus of the protein. Both domains can
133 contribute to the specificity for a given genus or species of bacteria³⁸.

134 Although no bacteriophages that infect *Gardnerella* species have yet been isolated, prophages
135 encoding for endolysins are present in the *Gardnerella* genomes. Phage endolysins are a
136 potentially novel and promising approach to treat BV because *Gardnerella*, now generally
137 acknowledged as the central agent in the etiology of BV, has a thin cell wall. To develop
138 endolysins specific for *Gardnerella*, we used an *in silico* approach to identify the genes
139 encoding endolysins. We cloned and sequenced 14 such genes, demonstrated the lytic activity
140 and specificity of purified recombinant proteins for *Gardnerella* spp. and engineered an enzyme
141 with enhanced activity by domain shuffling. Moreover, we demonstrate the efficacy and
142 specificity of this engineered endolysin on biofilms of *Gardnerella* in samples from patients
143 with BV.

144

145 **Material and Methods**

146 ***Bacterial strains and culture conditions***

147 *Atopobium vaginae*, *Gardnerella* spp., *Lactobacillus iners*, *Mobiluncus* spp., *Streptococcus*
148 *agalactiae*, *Prevotella bivia*, and and were obtained from the Laboratory of Bacteriology,
149 University of Ghent, Belgium. Other *Lactobacillus* spp. were obtained from the German

150 Collection of Microorganisms (DSMZ). *Gardnerella* strains were either grown on chocolate
151 (Choc) agar plates (Becton Dickinson) under anaerobic conditions in an anaerobic chamber
152 equipped with anaerobic atmosphere generation bags (Sigma Aldrich) for 24–48 h.
153 *Lactobacillus* spp. were cultured on Schaedler plates supplemented with vitamin K1 and 5 %
154 sheep blood (Becton Dickinson), anaerobically at 37 °C for 24–48 h. *A. vaginae*, *M. curtisii*,
155 *M. mulieris*, *S. agalactiae*, and *P. bivia* were either grown on Columbia blood agar plates,
156 supplemented with 5 % sheep blood (Becton Dickinson) or Schaedler agar plates supplemented
157 with vitamin K1 and 5 % sheep blood, anaerobically at 37 °C for 48 h. *Escherichia coli*
158 BL21(DE3) cells (New England Biolabs) were used for protein expression and were grown on
159 Luria Bertani (LB) agar plates (Becton Dickinson) or in LB (Luria/Miller) broth (Carl Roth)
160 supplemented with appropriate selection antibiotic, aerobically at 37 °C. Liquid cultures of all
161 species were done in New York City (NYC) broth III (10 mM HEPES (Sigma Aldrich), 15 g/L
162 Proteose Peptone (Sigma Aldrich), 3.8 g/L yeast extract (Thermo Fisher Scientific), 86 mM
163 sodium chloride (Carl Roth), 28 mM α -D-glucose (Sigma Aldrich)), supplemented with 10 %
164 horse serum (HS) (Thermo Fisher Scientific).

165 ***Identification of Gardnerella genes encoding endolysin within prophage regions***

166 Prophage regions in *Gardnerella* genomic sequences were identified by using PHASTER
167 (<https://phaster.ca/>) to scan translated nucleotide sequences of *Gardnerella* genome entries in
168 the NCBI database (<https://blast.ncbi.nlm.nih.gov>). Protein domain searches for endolysins
169 were performed using INTERPRO (<https://www.ebi.ac.uk/interpro/>) to identify predicted
170 enzymatically active domains in the corresponding amino acid sequence for each identified
171 phage endolysin.

172 ***Gene cloning and overexpression of phage endolysins***

173 Briefly, DNA of genes encoding wild-type or genetically engineered endolysins fused to a His₆-
174 tag was synthesized, cloned into the expression vector pET29b(+) and expressed in *E. coli*
175 BL21(DE3). Protein expression was induced by TB (Terrific Broth Medium; 24 g/L Bacto

176 Yeast Extract (Becton Dickinson), 12 g/L Bacto Tryptone (Becton Dickinson), 0.4 % glycerol
177 (87%; Applichem), 0.02 mM potassium phosphate monobasic (Sigma Aldrich), 0.07 mM di-
178 potassium hydrogen phosphate (Merck) and 1.5 % α -lactose monohydrate (Carl Roth)), by
179 incubating at 25 °C for 24 h, with shaking at 250 rpm/min. The overexpressed proteins were
180 purified by affinity chromatography on a nickel–nitrilotriacetic acid (Ni–NTA) affinity matrix
181 (HISTrap column) eluted with 50 mM MES (Carl Roth) pH 7, 150 mM NaCl (Carl Roth), 250
182 mM imidazole (Carl Roth) and followed by size exclusion chromatography. Fractions were
183 pooled and dialyzed against MES buffer (50 mM MES pH 5.5, 100 mM NaCl, 8 mM MgSO₄
184 (Sigma Aldrich)). Protein concentration was determined at OD 260/280 nm or by using the
185 PierceTM BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific).

186 ***Culture-based assessment of bactericidal activity***

187 Bacterial suspensions (OD₆₀₀ of 0.1, corresponding to approximately 10⁷–10⁸ CFU/ml) were
188 prepared by scraping the cells from confluent grown agar plates and diluting them into
189 NYCIII+ 10 % HS, pH 5.5. Reactions were performed in triplicate by mixing 10 μ l of endolysin
190 (200 μ g/ml) with 90 μ l bacterial suspension in the wells of a 96-well plate. Ten μ l MES buffer
191 without the endolysin was used as a control. The 96-well reaction plate was incubated
192 anaerobically at 37 °C for 5 h. Tenfold dilution series (10⁻¹ to 10⁻⁶) of the cell reaction mixtures
193 were prepared in NYCB+ 10 % HS and 2 μ l of each dilution were spotted onto Choc agar plates.
194 After anaerobic incubation at 37 °C for 48 h, colonies were counted, CFU/ml calculated, and
195 the log₁₀ reduction compared to MES buffer treated control was determined.

196 ***MIC assessment***

197 The minimum inhibitory concentration (MIC), which is a standard measure of the activity of
198 antimicrobials, was determined according to the Clinical and Laboratory Standards Institute
199 protocol (2018) *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria* ³⁹.
200 Bacterial suspensions of 10⁵ to 10⁶ CFU/ml in NYCIII+ 10 % HS were treated with a 1:2
201 dilution series of either PM-477 (starting concentration 64 μ g/ml) or the antibiotics

202 metronidazole (Gatt-Koller), tinidazole (Sigma Aldrich), or clindamycin (Clindamycin
203 hydrochloride, Sigma Aldrich), starting with a concentration of 128 $\mu\text{g/ml}$ and twofold dilution
204 down to 0.0625 $\mu\text{g/ml}$. Controls for growth in the absence of antimicrobials were also included.
205 OD_{620} was recorded by microplate reader (Tecan) after incubation at 37 °C for 48 h or, for some
206 fast-growing strains, after incubation for 24 h, and compared to $t=0$ values.

207 ***Phase contrast microscopy***

208 Dense bacterial suspensions were prepared in NYCIII+ 10 % HS either as *Gardnerella*
209 monocultures or as a co-cultures of *Gardnerella* and *Lactobacillus* strains at final $\text{OD}_{600}= 4$ for
210 each strain. Bacterial mixtures were centrifuged at 3,800 x g for 7 min at room temperature in
211 a benchtop centrifuge (Heraeus Instruments, Biofuge Pico). Supernatants were removed and
212 cell pellets were resuspended in 50 μl of PM-477 (460 $\mu\text{g/ml}$) or in MES buffer alone as a
213 negative control and incubated for 5 h at 37 °C under anaerobic conditions. Subsequently, 5 μl
214 of each bacterial suspension were placed on a glass slide, covered with a glass coverslip and
215 observed by phase contrast microscopy (Olympus BX41 microscope, magnification 1000x).

216 For the comparison of bacteriolytic and bactericidal effects, bacterial suspensions of
217 *Gardnerella swidsinskii* and *Gardnerella vaginalis* were prepared in NYCIII+ 10 % HS at a
218 final $\text{OD}_{600}= 1$. Bacterial suspensions of 50 μl were centrifuged at 3,800 x g for 7 min at room
219 temperature in a benchtop centrifuge (Heraeus Instruments, Biofuge Pico). Supernatants were
220 removed and pellets were resuspended in 50 μl of MES buffer containing PM-477 at 400 $\mu\text{g/ml}$,
221 200 $\mu\text{g/ml}$, 100 $\mu\text{g/ml}$, 50 $\mu\text{g/ml}$ or 25 $\mu\text{g/ml}$, or in MES buffer alone as a negative control, and
222 incubated for 5 h at 37 °C in anaerobic conditions. Subsequently, 5 μl of each bacterial
223 suspension were observed by phase contrast microscopy as above. To determine viability, 10
224 μl of the reaction mixture was serially diluted and spotted onto Choc agar plates. After
225 incubation at 37 °C for 48 h, the colonies were counted and CFU/ml was calculated.

226 ***Lytic effects of PM-477 and Octenisept® on ex vivo BV patient samples as detected by***
227 ***fluorescence in situ hybridization (FISH) microscopy***

228 Vaginal samples were collected from randomly selected 24–49 year-old Caucasian women who
229 were previously diagnosed with BV according to the Amsel criteria ⁴⁰. In addition, the presence
230 of clue cells (epithelial cells covered with cohesive *Gardnerella* bacteria) was determined by
231 FISH microscopy ¹⁶. Fresh vaginal smears were collected with a swab and put in ESwab™
232 493C02 pre-filled vials (COPAN Diagnostics). The vials were vortexed gently, resulting in a
233 suspension that contained epithelial cells and vaginal bacteria. Four consecutive vaginal smears
234 from each patient were pooled. The effects of 0.2, 2, 20 and 200 µg/ml of PM-477 after 2, 6,
235 and 24 h, respectively, were tested either at room temperature or 36 °C. Since the most
236 pronounced lytic effect on *Gardnerella* was observed after 24 h exposure to 200 µg/ml PM-477
237 at 36 °C (**Supplementary Table 1**), this condition was used for further studies. Subsequently,
238 vaginal swabs from 15 BV patients were collected, aliquoted, and mixed 1:1 (v/v) with 400
239 µg/ml PM-477 (final concentration of 200 µg/ml) or with MES buffer as a negative control, or
240 mixed 1:20 (v/v) with the disinfectant Octenisept® (Schülke) and incubated for 24 h at 36 °C.
241 Untreated samples were also included in the analyses as baseline controls. The samples were
242 fixed with Carnoy solution (alcohol/chloroform/acetic acid 6/3/1 by volume) ⁴¹. Fields of 10
243 mm x 10 mm were marked on SuperFrost slides (Langenbrinck, Emmendingen, Germany) with
244 a PAP pen (Kisker-Biotech, Steinfurt, Germany). Five µl aliquots of vortexed, fixed vaginal
245 smear sample were dropped onto the marked field. The slides were dried for 60 min at 50 °C
246 before FISH analysis.

247 For multicolor FISH analyses, we used the Gard662 *Gardnerella*-specific DNA hybridization
248 probe ⁴² and the universal bacterial probe Eub338 ⁴³. Oligonucleotide probes were synthesized
249 with a fluorescent dye (Cy3 or Cy5). The hybridization was performed at 50 °C as previously
250 described ⁴¹. The probe Ato291 was used for *Atopobium*, Lincrisp23-2 for *L. iners*, and Lcrisp16-
251 1 for *L. crispatus* ⁴². DAPI was used to visualize the vaginal epithelial cells (microphotographs
252 not shown). Changes in density and distribution of microbial species were monitored by using
253 a Nikon Eclipse 80i fluorescence microscope, a Nikon SHG1 camera and accompanying

254 software (Nikon, Tokyo, Japan). To avoid dispersion related biases (the thickness of smears on
255 the glass slide and the microbial distribution is uneven), bacteria were enumerated for
256 representative areas containing 10 epithelial cells as follows. For bacteria in low densities (e.g.
257 lactobacilli), larger areas, including at least 10 microscopic fields were evaluated and mean cell
258 numbers were expressed in relation to 10 epithelial cells. In areas with high local bacterial
259 concentrations (e.g. in patches of biofilms), where cells are adjacent and in part overlapping,
260 each 10 μm x 10 μm area covered with bacteria was counted as 500 bacterial cells. The numbers
261 were rounded to full 100s.

262 *Statistical analysis*

263 Where appropriate, data were log-normalized prior to applying statistical tests (e.g. for CFU/ml
264 values, and as indicated in the figure legends). When only two groups were compared, the
265 unpaired two-tailed Student's *t*-test was used as indicated in the respective figure legends.
266 Multiple groups were compared by two-tailed one-way ANOVA tests. The software used for
267 statistical analyses was GraphPad Prism8. Differences between groups were considered
268 statistically significant when $P \leq 0.05$.

269

270 **Results**


271 *Gardnerella* genomes contain prophage genes that encode active endolysins

272 Although no bacteriophages of *Gardnerella* species are known, multiple *Gardnerella* genomes
273 that have been sequenced contain DNA regions that are predicted to be of prophage origin^{44,45}.
274 To identify endolysins that might target specifically *Gardnerella*, we used Basic Local
275 Alignment Search Tool (BLAST) to search for sequences with similarities to known endolysin
276 genes in the prophage regions of published *Gardnerella* genomes. A total of 14 genes were
277 identified that encoded 1,4-beta-N-acetylmuramidases, with sequence similarity between 87 to
278 98 %, when compared to each other. Twelve genes encode a 306 residues protein whereas two
279 encode similar proteins that lack 55 residues at the C-terminus (**Supplementary Table 2**). The

280 sequences all encode domain structures common to all known endolysins: an N-terminal EAD
281 of the glycoside hydrolase family 25 (GH25) and a CBD, comprising two CW_7 motifs,
282 homologous to the CBD of Cpl-7 lysozyme, encoded by the *Streptococcus pneumoniae*
283 bacteriophage Cp-7. The sequences of these putative endolysins are 90–94% identical to some
284 proteins encoded by the genomes of *Atopobium* and *Bifidobacteriaceae* but < 70 % identical to
285 other endolysins, which may already indicate a high specificity for the genus *Gardnerella* (data
286 not shown).

287 We expressed the 14 predicted endolysin genes (EL1–EL14) as recombinant proteins in *E. coli*,
288 and ten (EL 1–7 and EL 10–12) yielded sufficient protein to perform further experiments. Their
289 lytic activities were tested on representatives of the four *Gardnerella* species: *G. vaginalis*
290 (ATCC 14018^T), *G. leopoldii* (UGent 09.48), *G. piovii* (UGent 18.01^T), and *G. swidsinskii*
291 (GS10234). Bacterial suspensions of 10⁷-10⁸ CFU/ml were incubated with each of the 10
292 endolysins (at 20 µg/ml) or with buffer as a negative control. After a 5 h incubation, we plated
293 the suspensions and quantified the surviving bacteria, measured as colony-forming units
294 (CFU)/ml (**Figure 1**). Most of the endolysins reduced the CFU/ml of all four *Gardnerella*
295 species by multiple log₁₀ units. Only EL5 and EL6 (one of the two truncated proteins mentioned
296 above) were completely inactive in this assay. EL3 and EL10 were the most active against all
297 four *Gardnerella* species tested, *G. swidsinskii* GS10234 being the most susceptible with a > 5
298 log₁₀-fold reduction in CFU/ml (**Figure 1**).

299



300

301 **Figure 1:** Wild-type endolysins are highly active against four different *Gardnerella* species.
 302 Suspensions of *G. vaginalis* (ATCC 14018T), *G. leopoldii* (UGent 09.48), *G. piotii* (UGent
 303 18.01T), and *G. swidsinskii* (GS10234) were treated with recombinant endolysins prepared by
 304 expression of the naturally occurring genes (EL1–EL7 and EL10–EL12) (see Methods) and the
 305 log₁₀ reduction in viable CFU/ml was determined. The log₁₀ reduction was calculated by
 306 comparing the CFU/ml after endolysin treatment with that of the buffer control (w/o). LOD
 307 indicates the limit of detection.

308

309

310 *Engineering of a Gardnerella endolysin with enhanced bactericidal activity*

311 To increase the lytic activity of the endolysins identified above, we used domain shuffling^{46,47}
 312 to recombine systematically ten of the EADs encoded by the newly identified endolysin genes
 313 EL 1–7 and EL 10–12 (annotated as H1–7 and H10–12) with nine CBDs encoded by EL1–5,
 314 EL7 and EL10–12 (annotated as B1–5, B7, and B10–12; since EL6 was inactive, we did not
 315 use its truncated CBD). All of the 81 resulting chimeric proteins were expressed in *E. coli* and
 316 purified by means of their N-terminal His tags. We tested these chimeric endolysins for their
 317 bactericidal activity on the abovementioned *Gardnerella* strains and compared their activity to
 318 that of the 10 wild-type endolysins (**Figure 2**).

319

H1	Gv_ATCC 14018 ^T	-1.9	-1.3	-0.9	-3.5	-0.4	-0.3	-0.2	-1.4
	Gl_UGent 09.48	-1.6	-1.2	-1.0	-3.5	-1.2	-1.1	-2.5	-5.4
	Gp_UGent 18.01 ^T	-1.1	-1.3	-2.9	-4.3	-1.6	-1.4	-3.1	-4.1
	Gs_GS10234	0.1	0.7	0.4	0.0	0.1	0.5	0.4	0.0
H2	Gv_ATCC 14018 ^T	-1.3	-1.5	-1.1	-3.8	-1.2	-1.3	-0.9	-3.3
	Gl_UGent 09.48	-0.3	-0.1	-0.4	-1.8	-0.8	-0.4	-0.7	-2.4
	Gp_UGent 18.01 ^T	-0.9	-1.4	-0.9	-3.1	-2.0	-2.2	-1.3	-4.2
	Gs_GS10234	-1.7	-1.1	-1.4	-3.2	-1.6	-1.2	-1.2	-3.9
H3	Gv_ATCC 14018 ^T	-0.8	-1.3	-0.8	-2.3	-0.2	-0.4	-0.4	-0.3
	Gl_UGent 09.48	-0.8	-1.3	-0.8	-2.3	-0.2	-0.4	-0.4	-0.3
	Gp_UGent 18.01 ^T	-0.2	-0.9	-0.3	-2.1	-0.2	-1.2	-0.6	-2.5
	Gs_GS10234	-0.8	-0.2	-1.5	-0.2	-0.9	-0.3	-2.1	-0.2
H4	Gv_ATCC 14018 ^T	-0.7	-0.7	-0.3	-1.9	-0.8	-0.7	-0.7	-2.3
	Gl_UGent 09.48	-2.9	-2.1	-1.6	-5.4	-2.3	-1.8	-1.6	-4.5
	Gp_UGent 18.01 ^T	-3.0	-2.0	-1.6	-5.4	-1.9	-1.4	-1.2	-4.0
	Gs_GS10234	0.0	0.4	0.2	-0.3	-0.4	-0.5	-0.4	-2.0
H5	Gv_ATCC 14018 ^T	-1.8	-3.0	-2.2	-4.5	0.2	0.3	-0.1	-0.1
	Gl_UGent 09.48	-1.6	-2.1	-1.2	-3.2	-1.6	-2.1	-1.2	-3.2
	Gp_UGent 18.01 ^T	-1.6	-2.1	-1.2	-3.2	-1.6	-2.1	-1.2	-3.2
	Gs_GS10234	-1.6	-2.1	-1.2	-3.2	-1.6	-2.1	-1.2	-3.2
H6	Gv_ATCC 14018 ^T	-1.6	-1.2	-0.9	-3.3	-1.6	-1.2	-0.9	-3.2
	Gl_UGent 09.48	-1.0	-1.3	-2.6	-6.7	-3.6	-3.3	-3.8	-6.7
	Gp_UGent 18.01 ^T	-0.9	-1.1	-0.3	-2.8	-1.5	-2.2	-0.6	-3.8
	Gs_GS10234	-3.0	-2.9	-1.9	-4.8	-3.0	-2.9	-1.9	-4.8
H7	Gv_ATCC 14018 ^T	-1.5	-2.2	-1.2	-4.2	-2.5	-3.6	-1.1	-4.7
	Gl_UGent 09.48	-0.5	-0.7	-0.6	-1.8	-5.1	-4.7	-2.4	-1.6
	Gp_UGent 18.01 ^T	-2.4	-1.6	-1.6	-4.4	-2.9	-3.3	-1.8	-4.8
	Gs_GS10234	-1.6	-2.0	-0.8	-4.2	-1.3	-1.9	-0.5	-3.7
H8	Gv_ATCC 14018 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gl_UGent 09.48	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gp_UGent 18.01 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gs_GS10234	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
H9	Gv_ATCC 14018 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gl_UGent 09.48	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gp_UGent 18.01 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gs_GS10234	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
H10	Gv_ATCC 14018 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gl_UGent 09.48	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gp_UGent 18.01 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gs_GS10234	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
H11	Gv_ATCC 14018 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gl_UGent 09.48	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gp_UGent 18.01 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gs_GS10234	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
H12	Gv_ATCC 14018 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gl_UGent 09.48	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gp_UGent 18.01 ^T	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2
	Gs_GS10234	-1.3	-1.3	-0.6	-3.8	-1.6	-2.0	-0.8	-4.2

320

321 **Figure 2:** Domain swapping increases the lytic activity of engineered endolysins. Eighty-one

322 constructs comprising all possible combinations of the EAD (H) and CBD (B) domains of 10


323 wild-type endolysins were tested on four different *Gardnerella* species as in Figure 1. The
324 values represent the log₁₀ of the ratio of viable cells (CFU/ml; mean of triplicate assays) in
325 endolysin-treated suspensions of *Gardnerella* compared to buffer control-treated suspensions
326 of the species, as indicated. Blue shades indicate higher bactericidal effect (high reduction in
327 viable CFU/ml) compared to the wild-type endolysin, red shades indicate lower bactericidal
328 effect, and white coloring indicates equal reduction compared to wild-type endolysin (boxed in
329 black). The endolysin candidate with the highest average reduction over four *Gardnerella*
330 species is boxed in yellow.

331
332 Overall, *G. swidsinskii* GS10234 was most sensitive to most endolysins – wild-type and
333 chimeric. Two of the chimeric endolysins, H2B10 and H2B11, were more active than any wild-
334 type enzyme against all four *Gardnerella* strains, whereas others were more active than any
335 wild-type endolysin against some strains (e.g. H2B12, H5B3, H5B4, H7B3 and H7B11)
336 (**Figure 2**). Overall, chimeric endolysins combining domains H2, H7 or H10 with domains B10,
337 B11 or B12 showed highest bactericidal activity. The combination of H2 and B10 was most
338 effective against any of the four strains and reduced their viability by an average of 4.3 log₁₀
339 CFU/ml. We designated this construct PM-477 and chose it for further development as a
340 candidate for the treatment of BV.


341 342 ***Specificity of PM-477 for the genus Gardnerella***

343 We characterized the activity and specificity of PM-477 against panels of 13 *Gardnerella*
344 strains of the four species described above, 12 strains of vaginal lactobacilli (including *L.*
345 *crispatus*, *L. jensenii* and *L. gasseri*, selected as representative of the healthy vaginal
346 microbiome) and nine other species typically found in BV, by using the quantitative assay for
347 bacterial viability described above. The engineered endolysin caused a 4–5 log₁₀-fold loss of
348 viability in three *Gardnerella* strains (Gs_GS10234, Gs_GS9838-1^T, Gp_UGent 18.01^T), a 2–

349 3 log₁₀-fold loss of viability in five strains (Gv_ATCC 14018^T, Gv_BV50.1, Gl_UGent 09.48,
 350 Gp_P80275, Gs_BV7.1), and a 1–2 log₁₀-fold loss of viability in a further five strains
 351 (Gv_UGent 09.07, Gv_UGent 09.01, Gl_BV13.2, Gl_BV86.5, Gp_UGent 21.28) (**Figure 3A**).
 352
 353 3A




354
 355 3B



356

357 3C



358

359 **Figure 3:** PM-477 is highly specific for *Gardnerella* and spares lactobacilli and other BV
 360 associated microbiome components. (a) *Gardnerella* strains, (b) *Lactobacillus spp.*, (c) and
 361 *Mobiluncus curtisii*, *Mobiluncus mulieris*, *Streptococcus agalactiae*, *Atopobium vaginae* and
 362 *Prevotella bivia* were tested for their susceptibility to PM-477 (20 µg/ml for 5h; treated, black
 363 squares) and compared to buffer control-treated (untreated, white circles) bacteria suspensions.
 364 For statistical purposes CFU/ml values from the untreated and the treated groups were log-
 365 normalized prior to applying the unpaired two-tailed multiple Student's *t*-test. *P*-values ≤ 0.05
 366 were considered statistically significant; ** *P* ≤ 0.01, *** *P* ≤ 0.001, **** *P* ≤ 0.0001.


367

368 The same treatment of lactobacilli, by contrast, had no statistically significant effect on the
 369 viability of any of the 12 strains tested (**Figure 3B**). It also had no effect on strains of *Atopobium*
 370 *vaginae*, *Mobiluncus mulieris*, *Prevotella bivia* and *Streptococcus agalactiae*, and had only a
 371 minor effect on one of three strains tested of *Mobiluncus curtisii* (**Figure 3C**). (In the cases of
 372 *Atopobium vaginae* and *Prevotella bivia* the cells either grew poorly or died rapidly upon

373 transfer from agar plates to suspension, even without treatment.) Thus, the engineered endolysin
374 PM-477 is highly selective for *Gardnerella*: it kills strains of each of the four main species ²³,
375 without harming beneficial lactobacilli or other species typical of the vaginal microbiome.
376 The genus-specific bacteriolytic effect of PM-477 was confirmed by microscopy in mixed
377 cultures of *Gardnerella* and lactobacilli. These two genera can be distinguished by their distinct
378 morphologies: *Gardnerella* cells are small coccoidal rods, whereas lactobacilli form mostly
379 long and thick rods. PM-477 (at 460 µg/ml for 5 h) lysed *G. vaginalis* and *G. swidsinskii* cells
380 in mono-culture and selectively lysed them in mixed cultures of *G. vaginalis* and *L. crispatus*
381 and of *G. swidsinskii* and *L. gasseri*, respectively, while the lactobacilli in these mixed cultures
382 were unaffected (**Figure 4A**).

383


384 4A



385

386 4B


Bacteriolytic effect of PM-477 on *G.vaginalis*



387

388 4C


Bacteriolytic effect of PM-477 on *G.swidsinskii*



389

390 4D


Bactericidal effect of PM-477 on *G.vaginalis*



391

392 4E

Bactericidal effect of PM-477 on *G.swidsinskii*



393

394 **Figure 4:** PM-477 selectively kills *Gardnerella* in a co-culture with lactobacilli. **A**, Phase
395 contrast microscopy of dense cultures of *G. vaginalis* (ATCC14018T) (first row) and *G.*
396 *swidsinskii* (GS10234) (second row), or co-cultures of *G. vaginalis* (ATCC14018T) and *L.*
397 *crispatus* (LABCRI FB020-08c) (third row), as well as *G. swidsinskii* (GS10234) and *L. gasseri*
398 (LAB GAS LMG 9203T) (fourth row) treated with PM-477 (460 µg/ml for 5h) or with buffer
399 (control). **B** and **C**, Cell counts of *Gardnerella* cells determined by phase contrast microscopy
400 after treatment with 25–400 µg/ml PM-477 for 5h or with buffer (Ctr). **D** and **E**, Viable cells

401 remaining (\log_{10} reduction CFU/ml compared to the buffer-treated control) in suspensions of
402 *Gardnerella* treated with 25–400 $\mu\text{g/ml}$ PM-477 for 5h.

403
404 We compared the bactericidal and bacteriolytic effects of PM-477 on *G. vaginalis* and *G.*
405 *swidsinskii* by treating suspensions of the bacteria with 25–400 $\mu\text{g/ml}$ PM-477 for 5 h and then
406 counting the cell numbers by microscopy and determining their viability by quantitative plating
407 (**Figure 4B–E**). The highest concentration of PM-477 (400 $\mu\text{g/ml}$) decreased the number of
408 cell-like structures by only 80–90 % (**Figure 4B, C**), whereas the same treatment resulted in a
409 $\geq 5.6 \log_{10}$ reduction in viable cells. This indicates that PM-477 may kill before fully dissolving
410 bacterial cells, resulting in visible but dead cell-like structures seen under the microscope
411 (**Figure 4D, E**).

412

413 *Efficacy of PM 477 compared to standard antimicrobials*

414 To compare the efficacy of PM-477 in suspension to the standard antimicrobials used to treat
415 BV, we determined the minimum inhibitory concentration (MIC)_s of PM-477, CLI, MDZ and
416 TDZ for 20 strains of *Gardnerella* by following the Clinical and Laboratory Standards Institute
417 protocol³⁹. All the *Gardnerella* species tested were highly susceptible to PM-477 with a MIC₉₀
418 value (the MIC value which inhibits 90 % of strains) of 8 $\mu\text{g/ml}$ (**Table 1**).

419

420 **Table 1:** Minimum inhibitory concentration (MIC) of PM-477 and the antibiotics CLI, MDZ,
421 and TDZ for various *Gardnerella* spp. and *Lactobacillus* spp. (R) Resistance, defined as ≥ 32
422 $\mu\text{g/ml}$ for MDZ and TDZ, and $\geq 8 \mu\text{g/ml}$ for CLI, according to international standards.


<i>Gardnerella</i> spp.			MIC of Antimicrobials [$\mu\text{g/ml}$]			
Name	Strain	Clade	PM-477	CLI	MDZ	TDZ
<i>G. vaginalis</i> (Gv9)	ATCC 14018T	IB	1	0.25	8	128 (R)
<i>G. vaginalis</i> (Gv1)	UGent 09.07	IA	2	0.25	>128 (R)	>128 (R)
<i>G. vaginalis</i> (Gv5)	UGent 09.01	IB	0.25	0.13	8	4
<i>G. vaginalis</i> (Gv8)	UGent 25.49	IB	0.13	<0.06	8	4
<i>G. vaginalis</i> (BV50)	SJHBruges isolate		8	0.25	32	64 (R)
<i>G. vaginalis</i> (BV111)	SJHBruges isolate		2	0.125	8	4
<i>G. vaginalis</i> (FB049)	SJHBruges isolate		4	0.5	16	8
<i>G. vaginalis</i> (FB061)	SJHBruges isolate		8	0.25	8	4
<i>G. leopoldii</i> (G111)	UGent 09.48	II	4	0.5	128 (R)	128 (R)
<i>G. leopoldii</i> (BV13)	SJHBruges isolate		4	0.5	>128 (R)	>128 (R)
<i>G. leopoldii</i> (BV86)	SJHBruges isolate		1	0.25	>128 (R)	>128 (R)
<i>G. piovii</i> (Gp17)	UGent 18.01T	III	8	0.5	16	64 (R)
<i>G. piovii</i> (Gp22)	UGent 21.28	III	2	0.25	64 (R)	>128 (R)
<i>G. piovii</i> (P80275)	UGent isolate		1	0.5	16	32
<i>G. piovii</i> (FB041)	UGent isolate		4	1	32	64 (R)
<i>G. piovii</i> (VMF1800 SVT21)	SJHBruges isolate		8	1	32	64 (R)
<i>G. swidsinskii</i> (Gs23)	GS 10234	IV	0.5	0.25	64 (R)	>128 (R)
<i>G. swidsinskii</i> (Gs24)	GS 9838-1T	IV	0.25	<0.06	>128 (R)	>128 (R)
<i>G. swidsinskii</i> (BV7)	SJHBruges isolate		1	0.5	>128 (R)	128 (R)
<i>G. swidsinskii</i> (BV112)	SJHBruges isolate		1	0.06	64 (R)	64 (R)
<i>L. crispatus</i>	DSM 20584		>128	4	>128	>128
<i>L. gasseri</i>	DSM 20077		>128	64	>128	>128
<i>L. jensenii</i>	PB2003-073-T2-3		>128	2	>128	>128

423 (R) Resistance, defined as $\geq 32 \mu\text{g/ml}$ for MDZ and TDZ and $\geq 8 \mu\text{g/ml}$ for CLI according to
424 international standards.

425
426 The *G. swidsinskii* strains had MICs in the range of 0.25–1 $\mu\text{g/ml}$, whereas the *G. vaginalis*
427 strains had MICs of 0.13–8 $\mu\text{g/ml}$, and *G. leopoldii* and *G. piovii* strains had MICs of 1–8 $\mu\text{g/ml}$.
428 Among this small number of strains tested for each species, there was no evidence that the four
429 *Gardnerella* species differed with regard to their susceptibility to PM-477. Whereas 12 of the
430 20 *Gardnerella* strains were resistant to MDZ and 15 were resistant TDZ, CLI was effective
431 against all strains at MICs $\leq 1 \mu\text{g/ml}$. All tested strains of three *Lactobacillus* species (*L.*
432 *crispatus*, *L. gasseri*, and *L. jensenii*) were resistant to the highest concentrations of PM-477,
433 MDZ, and TDZ (MICs > 128 $\mu\text{g/ml}$), whereas only one strain was resistant to CLI.
434 ***Efficacy of PM-477 against biofilms of Gardnerella in human BV samples***


435 To analyze the efficacy of PM-477 in a physiological environment that resembles closely the
 436 *in vivo* situation, we treated vaginal swabs from 15 BV patients, and analyzed them by
 437 fluorescence in-situ hybridization (FISH).

438



439

440 5B



441

442 **Figure 5:** PM-477 dissolves the *Gardnerella*-dominated biofilm on exfoliated vaginal
443 epithelial cells from BV patients. **A,** Representative examples of multi-color FISH with Gard
444 Cy3 probe (*Gardnerella*, yellow fluorescence) and universal Eub 338 Cy5 probe (all bacteria,
445 red fluorescence) in 400x magnification (where not stated otherwise) for patients 11, 12 and 15.
446 *Baseline (prior to treatment):* *Gardnerella* bacteria are cohesive and adherent to epithelial cells
447 forming dense biofilm patches on the surface of clue cells which is apparent due to background
448 fluorescence. The attachment of *Gardnerella* biofilm to epithelial cells can be seen especially
449 well in DAPI stains and on zoomed original microphotographs (DAPI microphotographs are
450 added to supplementary material together with all other original microphotographs of Figure 5)
451 *Control:* *Gardnerella* dominated biofilms in buffer-treated controls after 24 h incubation are
452 still dense in patient 11 and 12 and start to partially disintegrate in patient 15. *PM-477:* After
453 incubation with PM-477, the *Gardnerella* biofilm is completely disintegrated in all patients.
454 The disappearance of intense yellow fluorescent *Gardnerella* bacteria unmasks the red
455 fluorescence of still intact bacterial mass. Octenisept: similar to PM-477, Octenisept massively
456 reduces *Gardnerella* (yellow) but additionally nearly completely eliminates any other non-
457 *Gardnerella* bacteria (red). **B,** *Gardnerella* cell density in samples of patients 1-15 expressed
458 as the number of yellow bacteria counted in areas containing 10 epithelial cells (see methods
459 for a detailed description of the counting method)., p-values were calculated with ANOVA in
460 GraphPad Prism.

461
462 Areas of strong yellow fluorescence in the untreated (baseline) and buffer control-treated
463 samples indicated the presence of *Gardnerella*-dominated biofilm on exfoliated vaginal
464 epithelial cells (visible due to their pale autofluorescence and clearly corresponding to DAPI
465 counterstain), called clue cells. At baseline and after buffer treatment, the yellow fluorescence
466 of the *Gardnerella* probe outshines the red fluorescence of the probe for all bacteria, indicating

467 that the biofilm is composed in large part of *Gardnerella* cells. **Figure 5A** shows a total
468 resolution of the dense yellow staining on the epithelial cells upon treatment with PM-477.
469 Therefore, PM 477 proved strong bacteriolytic activity also in this *ex-vivo* setting. The
470 specificity of PM-477 was demonstrated by the remaining red signal from the universal
471 bacterial probe, indicating mostly non-*Gardnerella* cells. Only very few individual *Gardnerella*
472 cells seemed to remain associated with or in between the epithelial cells. However, the
473 comparison of bacteriolytic and bactericidal effect in **Figure 4B-E** would indicate that these
474 might be dead cell-like structures with sufficient DNA associated to them to hybridize the FISH
475 probes. In contrast to PM-477, Octenisept killed and lysed both the *Gardnerella* and other
476 bacterial cells non-specifically, as indicated by the visible reduction of both types of
477 fluorescence.

478 The effect of treatment was also quantified by counting the number of bacterial cells per 10
479 epithelial cells in representative fields of vision (**Figure 5B**). When compared with the baseline
480 samples, no significant changes were observed upon incubation with the buffer control,
481 indicating that the vaginal microbiome was generally stable over the time-course of the
482 experiment. PM-477 significantly reduced *Gardnerella* cells in the patient samples (median of
483 300 cells/10 epithelial cells) when compared to baseline (median of 1200 cells/10 epithelial
484 cells, $p=0.02$) and when compared to the buffer control-treated samples (median of 900 cells/
485 10 epithelial cells, $p=0.007$): 3 of the 15 samples showed a >500-fold reduction in *Gardnerella*
486 load, 4 showed a >100-fold reduction, 7 a >10-fold reduction and 11 a >2-fold reduction (data
487 for individual patient samples are presented in **Supplementary Table 3**).

488 The effects of PM-477 on *Gardnerella* were similar to those of Octenisept®. Unlike PM-477,
489 however, the lytic activity of the disinfectant was not specific for *Gardnerella* but affected all
490 bacteria (**Figure 5A, Supplementary Table 3**).

491 Two other potential BV associated bacteria, *A. vaginae* and *L. iners*, as well as *L. crispatus*,
492 were visualized by using selective FISH probes and their cell numbers per 10 epithelial cells

493 were counted (**Supplementary Table 3**). *A. vaginae*, *L. crispatus*, and *L. iners* were detected
494 in 10, 3 and 8 out of the 15 samples, respectively. Treatment with PM-477 reduced the median
495 cell counts of *L. iners* when compared to treatment with the buffer control in all samples
496 whereas the numbers of *L. crispatus* and *A. vaginae* bacteria were unaffected. Octenisept®
497 strongly reduced the cell counts of all three species.

498 In summary, these experiments provide a proof of the efficacy and selectivity of PM-477 for
499 the genus *Gardnerella* *in vitro* and also in the native BV biofilm.

500

501 **Discussion**

502 This is the first study to show that prophage-derived endolysins active on *Gardnerella* could be
503 used as an innovative treatment for bacterial vaginosis. Although no *Gardnerella* phages were
504 ever isolated in a lab, we were able to identify putative endolysins *in silico*. We expressed them
505 as recombinant proteins, improved their potency by systematic domain shuffling, demonstrated
506 their efficacy and selectivity *in vitro*, and, ultimately, on the native polymicrobial biofilms in
507 vaginal swabs from BV patients.

508 The currently available therapy of bacterial vaginosis is unsatisfactory. Antibiotic-centered
509 ‘standard-of-care’ treatment for BV is associated with a recurrence rate of ~60 % within 6
510 months, which may be explained by low efficacy of antibiotics on bacteria growing as biofilms,
511 but also by selective destruction of beneficial lactobacilli, which are thereby prevented from re-
512 establishing a protective environment ²⁶. Bacteriophage-derived endolysins have been
513 described as a potential alternative to antibiotics; they are both highly active on mucosal
514 biofilms and selective for individual genera or even species of bacteria ³⁵. Neither endolysins
515 nor whole phages specific to *Gardnerella* have been isolated previously, although the existence
516 of *Gardnerella*-specific phages has been postulated on the basis of genomic analyses ⁴⁴. We
517 identified *Gardnerella*-specific endolysin genes in the prophage-like genome sequences of
518 strains of *Gardnerella*. A similar approach was reported earlier, in which the phage lysin PlyCD

519 was identified by searching prophage-like sequences in the genomes of *Clostridium difficile*
520 strains⁴⁸. The fact that it is possible to predict and generate endolysins from prophage encoded
521 sequences in the genomes of unrelated species (*C. difficile* and *Gardnerella*) may indicate a
522 wide application of this approach, which is easily adaptable to other pathogenic bacteria.
523 We could show that the wild-type endolysins we identified and, even more so, our engineered
524 constructs, are highly bactericidal and selective for the genus *Gardnerella*.
525 Our engineered endolysin PM-477 is superior to the current standard of care antibiotics in that
526 it is active in the low µg/ml range and effective against all 20 of the *Gardnerella* strains we
527 tested, covering all four named species. In total, 60 % of the 20 strains were resistant to MDZ
528 and 75 % to TZD, reinforcing the notion that PM-477 may be more effective against BV than
529 currently used standard antibiotics.
530 The high resistance rate for MDZ, which was also reported elsewhere³¹, does not support the
531 finding that MDZ treatment temporarily relieves the symptoms in a majority of cases²⁶.
532 However, long-term cure is mostly not achieved with MDZ indicating that their effectiveness
533 may be reduced due to the high resistance rate of *Gardnerella* strains⁴⁹.
534 In our study, CLI was also effective against all the strains of different *Gardnerella* genotypes
535 we tested. Curiously, however, CLI has not shown superior efficacy when compared to MDZ
536 in clinical trials²⁶, which may indicate that BV biofilms are more tolerant to CLI than they are
537 of MDZ, thus compensating the higher rate of resistance against MDZ.
538 In conclusion, PM-477 is superior to all tested antibiotics because, unlike nitroimidazoles, it is
539 active on all *Gardnerella* strains and, unlike CLI, it does not kill lactobacilli. Antibiotics may
540 have the advantage over PM-477 of being active against a broader spectrum of pathogens. But,
541 unlike *Gardnerella*, these pathogens may not be pivotal in vaginal biofilm formation as is the
542 case in BV. Also, antibiotics typically have low activity on bacteria in biofilms²⁷ whereas our
543 *ex-vivo* data indicate that PM-477 works well on *Gardnerella* in vaginal biofilms.

544 Progress has been made in developing animal models for BV. For example, it was possible to
545 model some of the clinical characteristics of BV, such as epithelial exfoliation and clue cells
546 upon infection of mice with *Gardnerella*⁵⁰. However, it was not possible so far to model the
547 increase in pH and the diverse microbiome composition of human BV in animals. Therefore,
548 the next best and, arguably, more biologically relevant model to test the efficacy of PM-477 is
549 to use *ex-vivo* vaginal samples from BV patients, which contain clue cells, *i.e.* exfoliated
550 epithelial cells covered with a polymicrobial biofilm. The microbial populations of all the *ex*
551 *vivo* samples that we collected from 15 individual BV patients were clearly dominated by
552 *Gardnerella* and a substantial part of the *Gardnerella* cells adhered to the epithelial cells.
553 Treatment with PM-477 fully resolved the dense staining due to *Gardnerella* cells on the
554 epithelial cells while not affecting non-*Gardnerella* cells. Thus, we conclude that PM-477
555 quantitatively removes *Gardnerella* cells inside the polymicrobial biofilm on vaginal epithelial
556 cells *ex vivo*. Furthermore, it is effective in the environment of the vaginal fluid despite the
557 putative presence of proteases⁵¹ and other substances that might reduce its activity.

558 PM-477 shows promising results *in vitro* and *ex vivo* but we do not know yet whether selectively
559 removing *Gardnerella* will be sufficient to resolve the clinical symptoms of BV, which are
560 caused by a polymicrobial biofilm, and to allow lactobacilli to re-colonize the vagina. The
561 increasing evidence of the central role that *Gardnerella* plays in the etiology of BV¹⁵ and the
562 observation that BV seems not to be possible without *Gardnerella*²², indicates that this might
563 well be the case. The biomass of the polymicrobial biofilm consists largely of *Gardnerella* cells
564^{52,53}, so selective removal of *Gardnerella* should decimate the biofilm. Moreover, *Gardnerella*
565 mediates adhesion to the epithelial cells, whereas other bacteria, especially in smaller numbers,
566 may not be able to initiate biofilm formation on these cells⁵⁴. Other pathogens, especially
567 *Prevotella bivia*, synergize with *Gardnerella*, so when the latter is removed the viability of the
568 other pathogens is likely reduced as well^{55,56}. Removal of *Gardnerella* (and the concomitant
569 reduction in the viability of *P. bivia*) would reduce the levels of sialidase produced by

570 *Gardnerella* and *P. bivia* and allow the mucus layer to reform, in turn reducing the adherence
571 of the remaining BV pathogens and depriving them of carbon sources⁵⁷. Finally, the active
572 suppression of lactobacilli by *Gardnerella*²² would be released, allowing recolonization by
573 benign bacteria. This hypothesis has been investigated with *in vitro* biofilm models^{17,20}, and
574 PM-477 as a selective antimicrobial agent may be a very useful tool to further investigate the
575 role of *Gardnerella* in *ex vivo* as well as in *in vivo* studies.

576 In summary, we report here that an engineered, phage-derived endolysin has the potential to
577 completely disrupt the *Gardnerella*-dominated biofilm in vaginal swabs from patients with BV.
578 PM-477 is, thus a promising candidate for an effective treatment of recurrent BV, which
579 remains, despite decades of research, a major public health concern.

580

581 **Acknowledgements**

582 We thank Grégory Resch and Life Science Editors for scientific editing assistance during the
583 preparation of the manuscript.

584

585 **References**

- 586 1. Bautista CT, Wurapa E, Sateren WB, Morris S, Hollingsworth B, Sanchez JL. Bacterial
587 vaginosis: A synthesis of the literature on etiology, prevalence, risk factors, and
588 relationship with chlamydia and gonorrhea infections. *Mil Med Res*. 2016;3(1):4.
589 doi:10.1186/s40779-016-0074-5
- 590 2. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis:
591 a systematic review. *Am J Obstet Gynecol*. 2013;209(6):505-523.
592 doi:10.1016/j.ajog.2013.05.006
- 593 3. Tabatabaei N, Eren A, Barreiro L, et al. Vaginal microbiome in early pregnancy and
594 subsequent risk of spontaneous preterm birth: a case-control study. *BJOG An Int J*

- 595 *Obstet Gynaecol.* 2019;126(3):349-358. doi:10.1111/1471-0528.15299
- 596 4. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk
597 factors for adverse pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol.*
598 2007;21(3):375-390. doi:10.1016/j.bpobgyn.2006.12.005
- 599 5. Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P.
600 Reproductive outcome of patients undergoing in vitro fertilisation treatment and
601 diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic
602 PRISMA review and meta-analysis. *BJOG An Int J Obstet Gynaecol.* 2019;126(2):200-
603 207. doi:10.1111/1471-0528.15178
- 604 6. Mania-Pramanik J, Kerkar SC, Salvi VS. Bacterial vaginosis: A cause of infertility? *Int*
605 *J STD AIDS.* 2009;20(11):778-781. doi:10.1258/ijsa.2009.009193
- 606 7. van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial
607 vaginosis in infertility patients: a systematic review and meta-analysis. *Hum Reprod.*
608 2013;28(7):1809-1815. doi:10.1093/humrep/det096
- 609 8. Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges
610 ahead. *Lancet Infect Dis.* 2017;17(8):e235-e279. doi:10.1016/S1473-3099(17)30310-9
- 611 9. Hoang T, Toler E, DeLong K, et al. The cervicovaginal mucus barrier to HIV-1 is
612 diminished in bacterial vaginosis. Silvestri G, ed. *PLOS Pathog.* 2020;16(1):e1008236.
613 doi:10.1371/journal.ppat.1008236
- 614 10. Vanechoutte M. The human vaginal microbial community. *Res Microbiol.*
615 2017;168(9-10):811-825. doi:10.1016/j.resmic.2017.08.001
- 616 11. Ceccarani C, Foschi C, Parolin C, et al. Diversity of vaginal microbiome and
617 metabolome during genital infections. *Sci Rep.* 2019;9(1):1-12. doi:10.1038/s41598-
618 019-50410-x

- 619 12. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: Friend or Foe?
620 *Trends Microbiol.* 2017;25(3):182-191. doi:10.1016/j.tim.2016.11.007
- 621 13. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial
622 vaginosis. *Obstet Gynecol.* 2005;106(5):1013-1023.
623 doi:10.1097/01.AOG.0000183594.45524.d2
- 624 14. Machado A, Cerca N. Influence of Biofilm Formation by *Gardnerella vaginalis* and
625 Other Anaerobes on Bacterial Vaginosis. *J Infect Dis.* 2015;212(12):1856-1861.
626 doi:10.1093/infdis/jiv338
- 627 15. Muzny CA, Taylor CM, Swords WE, et al. An Updated Conceptual Model on the
628 Pathogenesis of Bacterial Vaginosis. - PubMed - NCBI. *J Infect Dis.*
629 2019;220(9):1399-1405. doi:10.1093/infdis/jiz342
- 630 16. Swidsinski A, Loening-Baucke V, Mendling W, et al. Infection through structured
631 polymicrobial Gardnerella biofilms (StPM-GB). *Histol Histopathol.* 2014;29(5):567-
632 587. doi:10.14670/HH-29.10.567
- 633 17. Castro J, Alves P, Sousa C, et al. Using an in-vitro biofilm model to assess the
634 virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella
635 vaginalis isolates. *Sci Rep.* 2015;5:11640. doi:10.1038/srep11640
- 636 18. Castro J, Jefferson KK, Cerca N, Biomédicas E, Biomédicas B, Salazar A. Innate
637 immune components affect growth and virulence traits of bacterial-vaginosis-
638 associated and non-bacterial-vaginosis-associated Gardnerella vaginalis strains
639 similarly. *Pathog Dis.* 2019;76(9):89. doi:10.1093/femspd/fty089
- 640 19. Murphy K, Mitchell CM. The Interplay of Host Immunity, Environment and the Risk
641 of Bacterial Vaginosis and Associated Reproductive Health Outcomes. *J Infect Dis.*
642 2016;214(Suppl 1):S29-S35. doi:10.1093/infdis/jiw140

- 643 20. Castro J, Machado D, Cerca N. Unveiling the role of Gardnerella vaginalis in
644 polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens
645 living as neighbors. *ISME J.* 2019;1306-1317. doi:10.1038/s41396-018-0337-0
- 646 21. Machado A, Jefferson KK a., Cerca N. Interactions between Lactobacillus crispatus
647 and bacterial vaginosis (BV)-associated bacterial species in initial attachment and
648 biofilm formation. *Int J Mol Sci.* 2013;14(6):12004-12012.
649 doi:10.3390/ijms140612004
- 650 22. Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis
651 of bacterial vaginosis: A conceptual model. *J Infect Dis.* 2014;210(3):338-343.
652 doi:10.1093/infdis/jiu089
- 653 23. Vaneechoutte M, Guschin A, Van Simaey L, Gansemans Y, Van Nieuwerburgh F,
654 Cools P. Emended description of Gardnerella vaginalis and description of Gardnerella
655 leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with
656 delineation of 13 genomic species within the genus Gardnerella. *Int J Syst Evol*
657 *Microbiol.* 2019;69(3):679-687. doi:10.1099/ijsem.0.003200
- 658 24. Hill JE, Albert AYK. Resolution and cooccurrence patterns of Gardnerella leopoldii, G.
659 Swidsinskii, G. Piotii, and G. Vaginalis within the vaginal microbiome. *Infect Immun.*
660 2019;87(12). doi:10.1128/IAI.00532-19
- 661 25. Shipitsyna E, Krysanova A, Khayrullina G, et al. Quantitation of all Four Gardnerella
662 vaginalis Clades Detects Abnormal Vaginal Microbiota Characteristic of Bacterial
663 Vaginosis More Accurately than Putative G. vaginalis Sialidase A Gene Count. *Mol*
664 *Diagnosis Ther.* 2019;23(1):139-147. doi:10.1007/s40291-019-00382-5
- 665 26. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and
666 Need for Innovation. *J Infect Dis* ®. 2016;214(S1):14-20. doi:10.1093/infdis/jiw159

- 667 27. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent *Gardnerella*
668 *vaginalis* biofilm persists on the vaginal epithelium after standard therapy with oral
669 metronidazole. *Am J Obstet Gynecol*. 2008;198(1):97.e1-6.
670 doi:10.1016/j.ajog.2007.06.039
- 671 28. Sobel JD. Vulvovaginal candidosis. *Lancet*. 2007;369(9577):1961-1971.
672 doi:10.1016/S0140-6736(07)60917-9
- 673 29. Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota
674 following a single dose of clindamycin results in sustained susceptibility to *Clostridium*
675 *difficile*-induced colitis. *Infect Immun*. 2012;80(1):62-73. doi:10.1128/IAI.05496-11
- 676 30. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. *Clostridium difficile*
677 infection following systemic antibiotic administration in randomised controlled trials: a
678 systematic review and meta-analysis. *Int J Antimicrob Agents*. 2016;48(1):1-10.
679 doi:10.1016/j.ijantimicag.2016.03.008
- 680 31. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis
681 (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and
682 clindamycin HHS Public Access. *Anaerobe*. 2017;47:115-119.
683 doi:10.1016/j.anaerobe.2017.05.005
- 684 32. Swidsinski A, Loening-Baucke V, Swidsinski S, Verstraelen H. Polymicrobial
685 *Gardnerella* biofilm resists repeated intravaginal antiseptic treatment in a subset of
686 women with bacterial vaginosis: a preliminary report. *Arch Gynecol Obstet*.
687 2015;291(3):605-609. doi:10.1007/s00404-014-3484-1
- 688 33. Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in
689 women with intractable bacterial vaginosis. *Nat Med*. 2019;25(10):1500-1504.
690 doi:10.1038/s41591-019-0600-6

- 691 34. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel
692 antimicrobials. *Future Microbiol.* 2012;7(10):1147-1171. doi:10.2217/fmb.12.97
- 693 35. Fischetti VA. Development of phage lysins as novel therapeutics: A historical
694 perspective. *Viruses.* 2018;10(6):310. doi:10.3390/v10060310
- 695 36. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive
696 pathogens. *Int J Med Microbiol.* 2010;300(6):357-362.
697 doi:10.1016/j.ijmm.2010.04.002
- 698 37. Schuch R, Lee HM, Schneider BC, et al. Combination therapy with lysin CF-301 and
699 antibiotic is superior to antibiotic alone for treating methicillin-resistant staphylococcus
700 aureus-induced murine bacteremia. *J Infect Dis.* 2014;209(9):1469-1478.
701 doi:10.1093/infdis/jit637
- 702 38. Oliveira H, Melo LDR, Santos SB, et al. Molecular Aspects and Comparative
703 Genomics of Bacteriophage Endolysins. *J Virol.* 2013;87(8):4558-4570.
704 doi:10.1128/jvi.03277-12
- 705 39. Carpenter DE, Karen Anderson Diane Citron CM, JoAnn Dzik-Fox BL, et al.
706 *Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria.*; 2018.
707 www.clsi.org. Accessed June 9, 2020.
- 708 40. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific
709 vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med.*
710 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9
- 711 41. Swidsinski A, Loening-Baucke V. Evaluation of Polymicrobial Involvement Using
712 Fluorescence In Situ Hybridization (FISH) in Clinical Practice. 2017:531-543.
713 doi:10.1007/978-3-662-52959-1_52
- 714 42. Swidsinski A, Guschin A, Tang Q, et al. Vulvovaginal candidiasis: histologic lesions

- 715 are primarily polymicrobial and invasive and do not contain biofilms. *Am J Obstet*
716 *Gynecol.* 2019;220(1):91.e1-91.e8. doi:10.1016/j.ajog.2018.10.023
- 717 43. Amann RI, Binder BJ, Olson RJ, Chisholm SW, Devereux R, Stahl DA. Combination
718 of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed
719 microbial populations. *Appl Environ Microbiol.* 1990;56(6).
- 720 44. Malki K, Shapiro JW, Price TK, et al. Genomes of Gardnerella Strains Reveal an
721 Abundance of Prophages within the Bladder Microbiome. Kuo C-H, ed. *PLoS One.*
722 2016;11(11):e0166757. doi:10.1371/journal.pone.0166757
- 723 45. Bohr LL, Mortimer TD, Pepperell CS. Lateral Gene Transfer Shapes Diversity of
724 Gardnerella spp. *Front Cell Infect Microbiol.* 2020;10. doi:10.3389/fcimb.2020.00293
- 725 46. Schmelcher M, Tchang VS, Loessner MJ. Domain shuffling and module engineering of
726 Listeria phage endolysins for enhanced lytic activity and binding affinity. *Microb*
727 *Biotechnol.* 2011;4(5):651-662. doi:10.1111/j.1751-7915.2011.00263.x
- 728 47. Nelson DC, Schmelcher M, Rodriguez-Rubio L, et al. Endolysins as Antimicrobials.
729 In: *Advances in Virus Research.* Vol 83. Academic Press Inc.; 2012:299-365.
730 doi:10.1016/B978-0-12-394438-2.00007-4
- 731 48. Wang Q, Euler CW, Delaune A, Fischetti VA. Using a novel lysin to help control
732 Clostridium difficile infections. *Antimicrob Agents Chemother.* 2015;59(12):7447-
733 7457. doi:10.1128/AAC.01357-15
- 734 49. Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gyax SE, Hilbert DW.
735 Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis.
736 *Diagn Microbiol Infect Dis.* 2016;84(1):1-3. doi:10.1016/j.diagmicrobio.2015.10.006
- 737 50. Morrill S, Gilbert NM, Lewis AL. Gardnerella vaginalis as a Cause of Bacterial
738 Vaginosis: Appraisal of the Evidence From in vivo Models. *Front Cell Infect*

- 739 *Microbiol.* 2020;10:168. doi:10.3389/fcimb.2020.00168
- 740 51. Muytjens CMJ, Vasiliou SK, Oikonomopoulou K, Prassas I, Diamandis EP. Putative
741 functions of tissue kallikrein-related peptidases in vaginal fluid. *Nat Rev Urol.*
742 2016;13(10):596-607. doi:10.1038/nrurol.2016.161
- 743 52. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent Biofilms in Bacterial
744 Vaginosis. *Obs Gynecol.* 2005;106(5):1013-1022.
- 745 53. Swidsinski A, Doerffel Y, Loening-Baucke V, et al. Gardnerella biofilm involves
746 females and males and is transmitted sexually. *Gynecol Obstet Invest.* 2010;70(4):256-
747 263. doi:10.1159/000314015
- 748 54. Alves P, Castro J, Sousa C, Cereija TB, Cerca N. Gardnerella vaginalis Outcompetes
749 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in
750 vitro biofilm formation model. *J Infect Dis.* 2014;210(4):593-596.
751 doi:10.1093/infdis/jiu131
- 752 55. Pybus V, Onderdonk AB. Evidence for a commensal, symbiotic relationship between
753 Gardnerella vaginalis and Prevotella bivia involving ammonia: Potential significance
754 for bacterial vaginosis. *J Infect Dis.* 1997;175(2):406-413.
755 doi:10.1093/infdis/175.2.406
- 756 56. Chen KCS, Forsyth PS, Buchanan TM, Holmes KK. Amine content of vaginal fluid
757 from untreated and treated patients with nonspecific vaginitis. *J Clin Invest.*
758 1979;63(5):828-835. doi:10.1172/JCI109382
- 759 57. Briselden AM, Moncla BJ, Stevens CE, Hillier SL. Sialidases (neuraminidases) in
760 bacterial vaginosis and bacterial vaginosis-associated microflora. *J Clin Microbiol.*
761 1992;30(3).